Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 29, 2023

Sulfonylureas as Second-Line Drugs for Cardiovascular Safety in Type 2 Diabetes

Diabetes Care


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes Care
Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study
Diabetes Care 2023 May 01;46(5)967-977, H Wang, RLM Cordiner, Y Huang, L Donnelly, S Hapca, A Collier, J McKnight, B Kennon, F Gibb, P McKeigue, SH Wild, H Colhoun, J Chalmers, J Petrie, N Sattar, T MacDonald, RJ McCrimmon, DR Morales, ER Pearson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading